Semenov Y - Search Results

1

Validation of case identification for hyperpigmentation in the setting of medication use using international classification of diseases coding.

Theodosakis N, Yoon J, Young K, Getachew E, Mostaghimi A, Semenov Y. Theodosakis N, et al. Among authors: semenov y. J Eur Acad Dermatol Venereol. 2022 Dec;36(12):e1001-e1003. doi: 10.1111/jdv.18402. Epub 2022 Jul 11. J Eur Acad Dermatol Venereol. 2022. PMID: 35789040 No abstract available.

2

Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study.

Zhang S, Tang K, Wan G, Nguyen N, Lu C, Ugwu-Dike P, Raval N, Seo J, Alexander NA, Jairath R, Phillipps J, Leung BW, Roster K, Chen W, Zubiri L, Boland G, Chen ST, Tsao H, Demehri S, LeBoeuf NR, Reynolds KL, Yu KH, Gusev A, Kwatra SG, Semenov YR. Zhang S, et al. medRxiv [Preprint]. 2023 Jan 18:2023.01.16.23284635. doi: 10.1101/2023.01.16.23284635. medRxiv. 2023. Update in: J Am Acad Dermatol. 2023 May;88(5):1024-1032. doi: 10.1016/j.jaad.2022.12.048 PMID: 36711758 Free PMC article. Updated. Preprint.

3

Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors.

Klebanov N, Pahalyants V, Murphy WS, Theodosakis N, Zubiri L, Klevens RM, Kwatra SG, Lilly E, Reynolds KL, Semenov YR. Klebanov N, et al. Oncologist. 2021 May;26(5):e898-e901. doi: 10.1002/onco.13768. Epub 2021 Apr 17. Oncologist. 2021. PMID: 33783099 Free PMC article.

4

Immunosuppressive biologics did not increase the risk of COVID-19 or subsequent mortality: A retrospective matched cohort study from Massachusetts.

Pahalyants V, Murphy WS, Klebanov N, Lu C, Theodosakis N, Klevens RM, Estir H, Lilly E, Asgari M, Semenov YR. Pahalyants V, et al. J Am Acad Dermatol. 2022 Jan;86(1):252-255. doi: 10.1016/j.jaad.2021.08.065. Epub 2021 Sep 10. J Am Acad Dermatol. 2022. PMID: 34509536 Free PMC article. No abstract available.

5

Validation of International Classification of Diseases Tenth Revision code for prurigo nodularis.

Roh YS, Marani M, Choi U, Sutaria N, Parthasarathy V, Deng J, Bordeaux ZA, Taylor MT, Semenov YR, Kwatra SG. Roh YS, et al. J Am Acad Dermatol. 2022 Aug;87(2):482-484. doi: 10.1016/j.jaad.2021.10.026. Epub 2021 Oct 22. J Am Acad Dermatol. 2022. PMID: 34695528 No abstract available.

6

Title: Immune-checkpoint inhibitor therapy is underutilized in the US: A multi-institutional cohort analysis.

Theodosakis N, Ugwu-Dike P, Pahalyants V, Reynolds K, Semenov Y. Theodosakis N, et al. Among authors: semenov y. Immunol Lett. 2022 Apr;244:43-44. doi: 10.1016/j.imlet.2021.12.005. Epub 2021 Dec 30. Immunol Lett. 2022. PMID: 34974035 No abstract available.

7

Reply to: "COVID-19 vaccination in IMID patients receiving rituximab: A personalized regimen should be formulated".

Pahalyants V, Murphy WS, Klebanov N, Lu C, Theodosakis N, Klevens MR, Estiri H, Lilly E, Asgari M, Semenov YR. Pahalyants V, et al. J Am Acad Dermatol. 2022 Jul;87(1):e47-e48. doi: 10.1016/j.jaad.2022.03.042. Epub 2022 Mar 29. J Am Acad Dermatol. 2022. PMID: 35364217 Free PMC article. No abstract available.

8

Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors.

Said JT, Liu M, Talia J, Singer SB, Semenov YR, Wei EX, Mostaghimi A, Nelson CA, Giobbie-Hurder A, LeBoeuf NR. Said JT, et al. JAMA Dermatol. 2022 May 1;158(5):552-557. doi: 10.1001/jamadermatol.2022.0354. JAMA Dermatol. 2022. PMID: 35416925 Free PMC article.

9

Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study.

Tiu BC, Zubiri L, Iheke J, Pahalyants V, Theodosakis N, Ugwu-Dike P, Seo J, Tang K, Sise ME, Sullivan R, Naidoo J, Mooradian MJ, Semenov YR, Reynolds KL. Tiu BC, et al. J Immunother Cancer. 2022 Jun;10(6):e004670. doi: 10.1136/jitc-2022-004670. J Immunother Cancer. 2022. PMID: 35705313 Free PMC article.

10

Impact of biologic therapy on cancer outcomes in patients with immune checkpoint inhibitor-induced bullous pemphigoid.

Said JT, Talia J, Wei E, Mostaghimi A, Semenov Y, Giobbie-Hurder A, Chen ST, LeBoeuf NR. Said JT, et al. Among authors: semenov y. J Am Acad Dermatol. 2023 Mar;88(3):670-671. doi: 10.1016/j.jaad.2022.06.1186. Epub 2022 Jun 30. J Am Acad Dermatol. 2023. PMID: 35779636 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

155 results

Search Page

Filters